Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.65 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | AGXT | P21549 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | CASR | P41180 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14655805 | 0.85 | TAAR1 (0.67) | TAAR1ADRB2CHRM2CHRM1CHRM3 | |
| SCHEMBL5954569 | 0.84 | SIGMAR1 (0.54) | TAAR1ADRB2CHRM2SLC2A1HDAC1 | |
| SCHEMBL4031646 | 0.84 | ADRB2 (0.62) | TAAR1ADRB2CHRM2CHRM1CHRM3 | |
| SCHEMBL8783348 | 0.84 | FFAR1 (0.54) | ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL28244453 | 0.81 | MTNR1A (0.66) | TAAR1ADRB2 | |
| SCHEMBL27922345 | 0.81 | MTNR1A (0.66) | TAAR1ADRB2 | |
| SCHEMBL9071087 | 0.81 | TAAR1 (0.71) | TAAR1ADRB2CHRM2CHRM1CHRM3 | |
| SCHEMBL29365903 | 0.81 | TAAR1 (0.71) | TAAR1ADRB2CHRM2CHRM1CHRM3 | |
| SCHEMBL11333474 | 0.81 | TAAR1 (0.71) | TAAR1ADRB2CHRM2CHRM1CHRM3 | |
| SCHEMBL2427142 | 0.81 | TAAR1 (0.71) | TAAR1ADRB2CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692096-B1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARM SPA (IT) | 2013-04-03 | — | — | EP | claimed |
| US-20100197799-A1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-08-05 | — | — | US | claimed |
| US-20070049643-A1 | Hydroxylamine derivatives | VICURON PHARMACEUTICALS INC. | 2007-03-01 | — | — | US | claimed |
| EP-1541547-A1 | Hydroxylamine derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-06-15 | — | — | EP | claimed |
| EP-1692096-B1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARM SPA (IT) | 2013-04-03 | — | — | EP | disclosed |
| US-20100197799-A1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-08-05 | — | — | US | disclosed |
| US-7763751-B2 | Hydroxylamine derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-07-27 | — | — | US | disclosed |
| US-20070049643-A1 | Hydroxylamine derivatives | VICURON PHARMACEUTICALS INC. | 2007-03-01 | — | — | US | disclosed |
| EP-1692096-A1 | HYDROXYLAMINE DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005058800-A1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-30 | — | — | WO | disclosed |
| EP-1541547-A1 | Hydroxylamine derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197799-A1 | HYDROXYLAMINE DERIVATIVES | C9, C1S, HTT | TAAR1 718/4885ADRB2 261/4885CHRM2 16/4885 |
| US-20070049643-A1 | Hydroxylamine derivatives | C9, C1S, HTT | TAAR1 707/4885ADRB2 238/4885CHRM2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.